Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 14/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040175 | 0.84 | SCD (0.62) | SCDCHRM4POLBRAB9AKDM4E | |
| SCHEMBL3046748 | 0.83 | SCD (0.60) | SCD | |
| SCHEMBL3049350 | 0.83 | SCD (0.64) | SCDCHRM4KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL3045601 | 0.81 | SCD (0.65) | SCDCHRM4 | |
| SCHEMBL3054034 | 0.80 | SCD (0.67) | SCDCYP3A4KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL3045565 | 0.79 | SCD (0.61) | SCDCHRM4POLBRAB9AKDM4E | |
| SCHEMBL12725843 | 0.79 | CYP1A2 (0.72) | SCDCHRM4POLBRAB9ACYP1A2 | |
| SCHEMBL246041 | 0.78 | SCD (1.00) | SCD | |
| SCHEMBL242781 | 0.75 | SCD (1.00) | SCD | |
| SCHEMBL243174 | 0.74 | SCD (0.90) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029722-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885CHRM4 3011/4885POLB 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.